Anthem Biosciences

Bengaluru, India Founded: 2007 • Age: 19 yrs Listed India's Most Valuable
Developer of integrated contract research development and manufacturing services
Request Access
Report Incorrect Data
Page last updated

About Anthem Biosciences

Anthem Biosciences is a publicly listed company based in Bengaluru (India) founded in 2007 by Ravindra K C, Ganesh Sambashivam, and Ajay Bharadwaj. Anthem Biosciences has raised $35.74 million across 4 funding rounds from investors including Department of Biotechnology, True North and Portsmouth Technologies Trials Unit. The company has 1,820 employees. Anthem Biosciences was last valued at $999.08 million in March 2021. Its chief executive, as recorded, is Ajay Bharadwaj. Its Indian entity Anthem Biosciences Limited reported revenue of ₹2,280 Cr. Anthem Biosciences offers products and services including Chemistry Services, Biology Services, and Biologics Services. Its focus areas include Biopharma Outsourcing, CDMO and Diversified. Its competitors include Syngene, Piramal Group and Panacea Biotec; 1 of its 3 listed competitors has raised funding.

Company details

Developer of integrated contract research development and manufacturing services. The company offers endtoend drug discovery, development and manufacturing support for small molecules, biologics and nutritional actives. It provides medicinal chemistry, process synthesis, analytical RD, toxicology and GLP preclinical testing under one roof. Services include microbial screening, protein expression, peptide synthesis, antibody drug conjugates and fermentation scaleup capable from milligram to tonne volumes. The infrastructure includes cGMP kilolabs, pilot manufacturing and AAALAC accredited vivarium for in vitro and in vivo studies. Quality control, regulatory compliance and analytical method development are embedded as part of the scientific service portfolio.

Recognitions & Rankings of Anthem Biosciences

India's Most Valuable Companies 2025 edition · Source: Hurun India
Valuation
₹42,700 Cr
1-year change
+185%
2024 #369 2023 #340 2022 #318
  • Headquarters Bengaluru, India
  • Employees 1,820
  • Founders Ravindra K C, Ganesh Sambashivam, Ajay Bharadwaj
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website anthembio.com
  • Social LinkedIn X Facebook
  • Legal Name Anthem Biosciences Limited
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹45,788 Cr

    ANTHEM · NSE

  • Share Price
    ₹813.95

    +0.14% today

  • Revenue
    ₹2,124 Cr

    FY 2025-26 · +15.2% YoY

  • EBITDA
    ₹810 Cr

    Margin 38.1%

  • Net Profit
    ₹607 Cr

    FY 2025-26 · +34.5% YoY

  • P/E (TTM)
    76.5x

    P/B 14.9x

  • ROE
    21.7%

    ROCE 29.3%

  • Debt / Equity
    0.03

    Interest cover 1.1x

  • Total Equity Funding
    $35.74M (USD)

    in 4 rounds

  • Latest Funding Round
    $33.41M (USD), Series A

    Mar 2021

  • Investors
    Department of Biotechnology

    & 3 more

  • Employee Count
    1,820

Products & Services of Anthem Biosciences

Anthem Biosciences offers a comprehensive portfolio of products and services, including Chemistry Services, Biology Services, and Biologics Services.

Chemistry Services
Scientific Services

Provides chemical discovery and development for life sciences applications.

Biology Services
Biological Research

Offers gene design and biologics manufacturing for health innovations.

Biologics Services
Manufacturing Services

Delivers biologics production with quality and compliance focus.

Funding Insights of Anthem Biosciences

Anthem Biosciences has successfully raised a total of $35.74M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $33.41 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $35.74M
  • Total Rounds 4
  • Last Round Series A — $33.41M
  • First Round $577,392

    (May 2008)

  • Investors Count 4

All 4 funding rounds of Anthem Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2021$33.41MSeries A$999.08MTrue North
–
Nov 2016$1.75MSeed$32.11BPortsmouthtechnologiestrialsunit
–
Jun 2012Grant––
Department of Biotechnology
May 2008$577,392Seed$•••••Portsmouthtechnologiestrialsunit
Muppala Raju
Valuation history
DateValuationStage
Mar 2021$999.08M••••••••
Nov 2016$32.11B••••••••
May 2008$•••••••••••••
Premium access

Full valuation and stage history of Anthem Biosciences

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $999.08M (Mar 2021). 4 investors in total: 3 institutional and 1 angel.

Investors in Anthem Biosciences

Anthem Biosciences has secured backing from 4 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Department of Biotechnology, True North and Portsmouth Technologies Trials Unit.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
True North
Private equity is invested by True North in mid-market companies.
truenorth.co.inMumbai, India
Portsmouth Technologies Trials Unit
Research in healthcare technologies is supported by this unit.
2018portsmouthtechnologiestrialsunit.org.ukPortsmouth, United Kingdom
Department of Biotechnology
Biotechnology research, guidelines, and funding by the Government of India.
1986dbtindia.gov.inDelhi, India

Muppala Raju

unknown_09ec73f6984148e7b
Premium access

Investor details for Anthem Biosciences

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Anthem Biosciences Limited (Anthem Biosciences)

Anthem Biosciences Limited is the primary company behind Anthem Biosciences. The boards of the 3 registered companies of Anthem Biosciences currently have 9 directors; the longest-serving is Ganesh Sambasivam, appointed in 2006. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ganesh Sambasivam
DIN 01469963
Director09 Nov 200619 yrs 11 moAnthem Cellutions ( India) Private Limited, Anthem Biosciences Limited
Ajay Bhardwaj
DIN 00333704
Managing Director09 Nov 200619 yrs 11 moAnthem Cellutions ( India) Private Limited, Anthem Bio Pharma Private Limited, Anthem Biosciences Limited
K Ravindra Chandrappa
DIN 01580534
Director09 Nov 200619 yrs 11 moAnthem Cellutions ( India) Private Limited, Anthem Biosciences Limited
Malay Barua Jiban
DIN 02324987
Director17 Jan 20197 yrs 9 moAnthem Bio Pharma Private Limited
Satish Chander Subbanna
DIN 02849420
Nominee Director09 Apr 20215 yrs 6 moAnthem Biosciences Limited
Shubha Kulkarni
DIN 03551350
Director27 Sep 20242 yrsAnthem Biosciences Limited
Ramadurai Ramesh
DIN 07109252
Director27 Sep 20242 yrsAnthem Biosciences Limited
Subramanian Madhavan
DIN 06451889
Director27 Sep 20242 yrsAnthem Biosciences Limited
Ravikant Uppal
DIN 00025970
Director27 Sep 20242 yrsAnthem Biosciences Limited

People of Anthem Biosciences

8 people are tracked at Anthem Biosciences (4 in leadership, 4 in team); the tracked headcount is 1,820.

NameRoleGroup
Ravindra K C
Co-Founder & COOLeadership
Ganesh Sambashivam
Co-Founder & CSOLeadership
Ajay Bharadwaj
Co-Founder & CEOLeadership
Gawir Baig
Chief Financial OfficerLeadership
Krithika Sm
Senior ExecutiveTeam
Dhinagaran S
Senior ExecutiveTeam
Narendra Kumar Thakshinamoorthy
Senior ExecutiveTeam
Karthi P
Senior ExecutiveTeam
Premium access

Complete people profiles for Anthem Biosciences

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Anthem Biosciences

Anthem Biosciences is a publicly listed company on the NSE with ticker symbol ANTHEM in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date21 Jul 2025
  • Listed onNSE: ANTHEM · BSE: 544449
  • Listed entityAnthem Biosciences Limited
  • Exchange sectorHealth technology
  • ISININE0CZ201020
  • Share price₹847.75 (-2.57% on the day) · 2026-10-14
  • Market capitalisation₹49,047 Cr
  • Price to earnings83.5
  • EPS (diluted, trailing year)₹10.15
  • Dividend yield0.23%
  • Volume (last session)544,948

Financials of Anthem Biosciences

Exchange-reported figures of Anthem Biosciences Limited, the listed company behind Anthem Biosciences (NSE: ANTHEM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,124 Cr
+15.2% YoY
EBITDA
₹810 Cr
+20.6% YoY
Profit After Tax
₹607 Cr
+34.5% YoY
Net Worth
₹3,043 Cr
+26.3% YoY
Total Assets
₹3,129 Cr
+23.0% YoY
Total Debt
₹53.93 Cr
-52.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1241,8451,4191,0571,2311,103633
Revenue growth+15.2%+30.0%+34.3%-14.2%+11.6%+74.4%-
EBITDA810671505431565408182
EBITDA margin+38.1%+36.4%+35.6%+40.8%+45.9%+37.0%+28.8%
Profit before tax824657477497546366121
Net profit60745236834440627192.64
Net profit margin+28.6%+24.5%+25.9%+32.6%+33.0%+24.6%+14.6%
EPS (₹)10.548.076.576.75462.08319.75110.63
Balance sheet
Total assets3,1292,5452,1821,8801,425829604
Net worth3,0432,4101,9251,7411,355701422
Total debt53.9311323912635.49100159
Cash & bank27517218434334940.7722.43
Net working capital837913806696631202121
Cash flow
Cash from operations844271140306333278166
Cash from investing(702)(147)(221)(376)(205)(196)(109)
Cash from financing(40.00)(136)(77.18)63.97181(63.27)(47.63)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue418611423550540483498525
Revenue growth (YoY)-22.6%+26.4%-15.0%+4.8%+59.6%---
Other income24.8952.1933.5348.2322.8114.0624.3727.85
EBITDA151267132218191195160195
EBITDA margin+36.0%+43.7%+31.2%+39.6%+35.4%+40.4%+32.0%+37.2%
Depreciation29.9939.5934.5333.5026.4530.4220.2819.99
Interest0.891.900.353.031.610.522.553.55
Profit before tax145278130230186178161200
Tax24.6488.1637.6656.1750.4695.6936.7137.60
Net profit12019092.8217313682.63124162
EPS (₹)2.113.341.643.092.421.470.002.84
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,0891,8411,4181,0571,2311,103633
Revenue growth+13.5%+29.9%+34.1%-14.2%+11.6%+74.4%-
EBITDA827689505431565408182
EBITDA margin+39.6%+37.4%+35.6%+40.8%+45.9%+37.0%+28.8%
Profit before tax903711485498547366121
Net profit68650637534540627192.64
Net profit margin+32.9%+27.5%+26.5%+32.6%+33.0%+24.6%+14.6%
EPS (₹)11.949.056.706.76462.60319.76110.63
Balance sheet
Total assets3,2662,6082,1251,8701,426829604
Net worth3,1852,4731,9331,7421,355701422
Total debt50.0311317311535.49100159
Cash & bank27016618434334940.6222.43
Net working capital761875787703631202121
Cash flow
Cash from operations889300164319333278166
Cash from investing(742)(250)(192)(378)(206)(196)(109)
Cash from financing(43.55)(68.47)(132)52.85181(63.27)(47.63)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue384582417552538479498525
Revenue growth (YoY)-28.7%+21.6%-16.4%+5.2%+58.9%---
Other income28.6061.6039.9253.8027.7337.8224.3427.83
Total expenses253316279327343281331324
EBITDA131267138226195198167201
EBITDA margin+34.1%+45.8%+33.1%+40.9%+36.3%+41.4%+33.5%+38.3%
Depreciation22.3126.2826.7523.9222.6120.9919.5019.11
Interest0.761.581.132.231.612.101.792.56
Profit before tax136301150253199213170207
Tax34.3689.0637.9954.8750.6090.2741.9136.67

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue418611423550540483498525
Revenue growth (YoY)-22.6%+26.4%-15.0%+4.8%+59.6%---
Other income24.8952.1933.5348.2322.8114.0624.3727.85
EBITDA151267132218191195160195
EBITDA margin+36.0%+43.7%+31.2%+39.6%+35.4%+40.4%+32.0%+37.2%
Depreciation29.9939.5934.5333.5026.4530.4220.2819.99
Interest0.891.900.353.031.610.522.553.55
Profit before tax145278130230186178161200
Tax24.6488.1637.6656.1750.4695.6936.7137.60
Net profit12019092.8217313682.63124162
EPS (₹)2.113.341.643.092.421.470.002.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1241,8451,4191,0571,2311,103633
Revenue growth+15.2%+30.0%+34.3%-14.2%+11.6%+74.4%-
Other income15685.7363.7013948.9837.2120.76
Total expenses1,3151,174914626666696451
Employee cost281260183153138142120
EBITDA810671505431565408182
EBITDA margin+38.1%+36.4%+35.6%+40.8%+45.9%+37.0%+28.8%
Depreciation13489.3781.8263.7057.7662.4061.58
Interest7.0610.539.668.7210.0916.9720.43
Profit before tax824657477497546366121
Tax23220611011214194.2727.96
Net profit60745236834440627192.64
Net profit margin+28.6%+24.5%+25.9%+32.6%+33.0%+24.6%+14.6%
EPS (₹)10.548.076.576.75462.08319.75110.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital1121121121148.788.488.38
Reserves & surplus2,9302,2981,8131,6271,346693413
Shareholders' funds (net worth)3,0432,4101,9251,7411,355701422
Minority interest0.000.000.000.000.000.000.00
Secured loans51.0710915111635.49100101
Unsecured loans2.864.3687.799.830.000.0057.52
Total debt53.9311323912635.49100159
Total liabilities3,1292,5452,1821,8801,425829604
Assets
Gross block1,5071,301996884707682567
Net block783705483449329361306
Capital work in progress26429734516415418.6849.81
Investments1,00743347249927320998.66
Inventories12534021112958.2335.06125
Sundry debtors591450490274326255105
Cash & bank balances27517218434334940.7722.43
Loans & advances14821313683.9691.5576.2051.39
Total current assets1,1381,1761,022830825407304
Total current liabilities300263216135194205184
Net working capital837913806696631202121
Total assets3,1292,5452,1821,8801,425829604
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash17218434334940.7722.4313.90
Net cash from operating activities844271140306333278166
Net cash from investing activities(702)(147)(221)(376)(205)(196)(109)
Net cash from financing activities(40.00)(136)(77.18)63.97181(63.27)(47.63)
Net change in cash103(12.08)(158)(6.06)30818.348.53
Closing cash27517218434334940.7722.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.2%+30.0%+34.3%-14.2%+11.6%+74.4%-
EBITDA growth+20.7%+32.9%+17.2%-23.8%+38.6%+124.1%-
PBT growth+25.5%+37.6%-4.0%-8.9%+49.4%+203.0%+9997.0%
Net income growth+34.5%+22.9%+6.7%-15.1%+49.5%+193.0%-
Revenue CAGR (3Y)+26.2%+14.4%+8.8%+18.7%---
EBITDA CAGR (3Y)+23.4%+5.9%+7.4%+33.3%---
Profitability & leverage
Net income margin+27.9%+24.5%+25.9%+36.4%+32.9%+24.6%+14.7%
Return on capital employed+29.3%+28.2%+24.0%+27.4%+49.4%+53.4%+23.4%
Return on net worth+21.7%+20.8%+20.0%+22.3%+39.4%+48.3%+22.0%
Debt / equity0.030.080.100.050.070.230.38
Long-term debt / equity0.010.040.060.030.010.100.23
Interest cover1.051.812.282.381.994.9116.98
Efficiency & per share
Fixed asset turnover1.511.611.511.331.771.771.12
Inventory turnover9.146.698.3311.2626.4013.755.05
Debtors turnover4.083.923.713.524.246.136.02
EPS (₹)10.548.076.576.75462.08319.75110.63
Dividend per share (₹)2.000.000.000.000.000.000.00
Book value per share (₹)54.1643.1034.4330.511,543.93826.75503.43
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue384582417552538479498525
Revenue growth (YoY)-28.7%+21.6%-16.4%+5.2%+58.9%---
Other income28.6061.6039.9253.8027.7337.8224.3427.83
Total expenses253316279327343281331324
EBITDA131267138226195198167201
EBITDA margin+34.1%+45.8%+33.1%+40.9%+36.3%+41.4%+33.5%+38.3%
Depreciation22.3126.2826.7523.9222.6120.9919.5019.11
Interest0.761.581.132.231.612.101.792.56
Profit before tax136301150253199213170207
Tax34.3689.0637.9954.8750.6090.2741.9136.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,0891,8411,4181,0571,2311,103633
Revenue growth+13.5%+29.9%+34.1%-14.2%+11.6%+74.4%-
Other income18210970.5213948.9837.2120.76
Total expenses1,2621,151913626666696451
Employee cost262252183153138142120
EBITDA827689505431565408182
EBITDA margin+39.6%+37.4%+35.6%+40.8%+45.9%+37.0%+28.8%
Depreciation99.5777.9481.4963.7057.7662.4061.58
Interest6.719.299.268.7110.0916.9720.43
Profit before tax903711485498547366121
Tax23320511011214194.2727.96
Net profit68650637534540627192.64
Net profit margin+32.9%+27.5%+26.5%+32.6%+33.0%+24.6%+14.6%
EPS (₹)11.949.056.706.76462.60319.76110.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital1121121121148.788.488.38
Reserves & surplus3,0722,3611,8211,6281,347693413
Shareholders' funds (net worth)3,1852,4731,9331,7421,355701422
Secured loans47.1710916710535.49100101
Unsecured loans2.864.365.999.830.000.0057.52
Total debt50.0311317311535.49100159
Total liabilities3,2662,6082,1251,8701,426829604
Assets
Gross block1,2901,208991884707682567
Net block613624478449329361306
Capital work in progress83.5257.9415614315318.5949.81
Investments1,38053347249927320998.66
Inventories11933921112958.2335.06125
Sundry debtors573448490274326255105
Cash & bank balances27016618434334940.6222.43
Loans & advances63.9115010180.4790.8176.2051.39
Total current assets1,0261,103986827824407304
Total current liabilities265228200123193205184
Net working capital761875787703631202121
Total assets3,2662,6082,1251,8701,426829604
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash16618434334940.6222.4313.90
Net cash from operating activities889300164319333278166
Net cash from investing activities(742)(250)(192)(378)(206)(196)(109)
Net cash from financing activities(43.55)(68.47)(132)52.85181(63.27)(47.63)
Net change in cash104(17.60)(159)(6.07)30818.198.53
Closing cash27016618434334940.6222.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.5%+29.9%+34.1%-14.2%+11.6%+74.4%-
EBITDA growth+20.0%+36.5%+17.2%-23.8%+38.7%+124.1%-
PBT growth+26.9%+46.8%-2.6%-8.9%+49.5%+203.0%+6.1%
Net income growth+35.6%+35.1%+8.8%-15.1%+49.6%+193.0%-
Revenue CAGR (3Y)+25.5%+14.3%+8.7%+18.7%+25.3%--
EBITDA CAGR (3Y)+24.3%+6.8%+7.4%+33.3%+48.8%--
Profitability & leverage
Net income margin+32.1%+27.5%+26.4%+36.5%+33.0%+24.6%+14.7%
Return on capital employed+31.0%+30.5%+24.7%+27.5%+49.4%+53.4%+24.9%
Return on net worth+23.7%+23.0%+20.4%+22.3%+39.5%+48.3%+24.6%
Debt / equity0.030.060.080.050.070.230.47
Long-term debt / equity0.010.030.040.030.010.100.31
Interest cover0.921.522.192.371.994.9116.98
Efficiency & per share
Fixed asset turnover1.671.671.511.331.771.771.17
Inventory turnover9.136.698.3211.2626.4013.755.83
Debtors turnover4.093.933.713.524.246.135.69
EPS (₹)11.949.056.706.76462.60319.76110.63
Dividend per share (₹)2.000.000.000.000.000.000.00
Book value per share (₹)56.7044.2434.5830.531,544.46826.76503.43

Timeline of Anthem Biosciences

7 dated milestones of Anthem Biosciences across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Anthem Biosciences is founded.
  2. Funding First funding round of $577K.
  3. Milestone Reaches Minicorn status.
  4. Milestone Reaches Decacorn status.
  5. Funding Latest funding round, Series A, of $33.4M.
  6. Milestone Reaches Soonicorn status.
  7. IPO Lists on the stock exchange (IPO).

Competitors of Anthem Biosciences

Anthem Biosciences has 3 listed competitors in our database, 1 of them funded. They include Syngene, Piramal Group and Panacea Biotec.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Syngene
syngeneintl.com1993Bengaluru, India$85.89M5,618
Provider of contract research and manufacturing services for both small molecules and biologics
Piramal Group
piramal.com1984Mumbai, India204
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
Panacea Biotec
panaceabiotec.com1984Ambala, India2,095
Developer of biosimilars, vaccines and natural products
Premium access

Detailed competitors of Anthem Biosciences

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Anthem Biosciences

The website of Anthem Biosciences (anthembio.com) receives about 9.8K visits a month and ranks #1,599,242 among all websites worldwide, #2,152 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    9.8K

    ▼ 13.6% vs previous month

  • Unique visitors
    5.3K

    per month

  • Global rank
    #1,599,242

    among all websites

  • Category rank
    #2,152

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Anthem Biosciences. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Kemwell Biopharma
kemwellbiopharma.com
100%
6.2K#2,788,016View details
The Pharma Times
thepharmatimes.in
63%
#5,879,772View details
Labiotech
labiotech.eu
58%
200.5K#249,174View details
LifeCell
lifecell.in
38%
115.7K#350,498View details
PlasmaGen BioSciences
plasmagen.com
31%
1.1K#12,142,620View details

Top companies in Biopharma Outsourcing & Drug Delivery

2 companies that operate in the same segment as Anthem Biosciences (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Laurus Labs
Pharmaceutical and biotechnology company
2005Hyderabad, Telangana, IndiaUSD 229.73 MUSD 726.15 M12,470
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M4,260
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Anthem Biosciences

ANTHEM: RS. 249.90 CRORES BSE BLOCK TRADE; FOR ~ 3,000,000 SHARES, AT RS. 833.00
Exchange Update • 17 days ago
Cupid, Avalon, Pine Labs, ACME Solar, Groww, Belrise: FTSE rebalancing, inflow preview - BusinessToday
Business Today • 1 month ago
Stock recommendations for 27 August from MarketSmith India
Mint • 2 months ago
Anthem Biosciences shares gain 2.11%, trading at Rs 871.00
Moneycontrol • 2 months ago
Anthem Biosciences Shares Rise 2.20% to Rs 859.50
Moneycontrol • 2 months ago
Anthem Biosciences shares decline 2.19% on Tuesday
Moneycontrol • 2 months ago
Anthem Biosciences shares gain over 2% today
Moneycontrol • 2 months ago
Trade Spotlight: How should you trade Hero MotoCorp, Anant Raj, Anthem Biosciences, KEI Industries, Escorts, BLS E-Services, and others on August 3?
Moneycontrol • 2 months ago
Anthem Biosciences shares gain 2.36% in today's session
Moneycontrol • 2 months ago
Buy Anthem Biosciences; target of Rs 850: Prabhudas Lilladher
Moneycontrol • 3 months ago
Premium access

Complete news archive for Anthem Biosciences

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anthem Biosciences

Anthem Biosciences was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Anthem Biosciences is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Ajay Bharadwaj is the CEO of Anthem Biosciences, as recorded in our data. They have also founded this company.

Anthem Biosciences is a funded company, having raised a total of $35.74M across 4 funding rounds to date. The company's 1st funding round was a Seed of $577.39K, raised on May 2008.

Anthem Biosciences has 1,820 employees.

The primary company behind Anthem Biosciences, Anthem Biosciences Limited, reported revenue of ₹2,280 Cr for FY 2026, up 15% year on year.

Developer of integrated contract research development and manufacturing services. The company offers endtoend drug discovery, development and manufacturing support for small molecules, biologics and nutritional actives. It provides medicinal chemistry, process synthesis, analytical RD, toxicology and GLP preclinical testing under one roof. Services include microbial screening, protein expression, peptide synthesis, antibody drug conjugates and fermentation scaleup capable from milligram to tonne volumes. The infrastructure includes cGMP kilolabs, pilot manufacturing and AAALAC accredited vivarium for in vitro and in vivo studies. Quality control, regulatory compliance and analytical method development are embedded as part of the scientific service portfolio.

Anthem Biosciences's top competitors include Syngene, Panacea Biotec and Piramal Group.

Anthem Biosciences offers Chemistry Services, Biology Services, and Biologics Services.

Yes, Anthem Biosciences is publicly traded on NSE under the ticker symbol ANTHEM.

Anthem Biosciences has 4 investors. Key investors include Department of Biotechnology, True North, Portsmouth Technologies Trials Unit, and Muppala Raju.

The valuation of Anthem Biosciences is $999.08M as of Mar 2021.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available